ABSTRACT. The incidence of DIC in 208 dogs with a malignant tumor was evaluated. The incidence of DIC was 9.6% in dogs with a malignant tumor which was a solid tumor in all. In 164 dogs with a malignant solid tumor, the incidence of DIC was 12.2%. The incidence of DIC in dogs with hemangiosarcoma, mammary gland carcinoma and adenocarcinoma of the lung was significantly higher than that in dogs with other malignant tumors. These results suggested that special care in looking for DIC should be taken in dogs with a malignant solid tumor.
Disseminated intravascular coagulation (DIC) is a complex syndrome characterized by excessive thrombin and plasmin formation, causing the consumption of platelets, coagulation factors and inhibitors, and secondary hyperfibrinolysis. Therefore, DIC shows a diffuse microthrombosis and bleeding tendency.
DIC was frequently diagnosed in dogs with an underlying disease such as malignant tumor, pancreatitis, sepsis, immune-mediated hemolytic anemia, hepatitis, heat stroke and trauma [1, 2] . Among these various underlying diseases, malignant tumor was reported to be the commonest cause of DIC in dogs [2] .
There are some reports concerning abnormal hemostasis or the incidence of DIC in several tumor diseases of dogs [3, 4, 9, 11] , but the incidence of DIC remains unclear in malignant tumor cases. This paper deals with the incidence of DIC in dogs with a malignant tumor. DIC was diagnosed by four or more abnormal findings among the following: low platelet count (< 150 × 10 3 /µl), prolonged PT (> 8.5 sec), prolonged APTT (> 18.0 sec), low plasma fibrinogen concentration (< 200 mg/dl), low plasma AT III activity (< 90%) and high serum FDP (≥ 10 µg/ml). DIC was also diagnosed by three or more of the above, when FDP, AT III or a platelet count was not performed.
Fisher's exact test was used to compare the groups with and without DIC. A p value of <0.05 indicated statistical significance.
A diagnosis of DIC was made in 20 of 208 dogs with a malignant tumor (9.6%)( Table 1 ). All cases of DIC were dogs with a malignant solid tumor, and none with a malignant hematopoietic tumor which included lymphoma (38 cases), acute myeloid leukemia (2 cases), malignant histiocytosis (2 cases), acute lymphoblastic leukemia (1 case) and chronic lymphoblastic leukemia (1 case). In contrast to human cases in which DIC occurs frequently, DIC appears to be uncommon in dogs with a malignant hematopoietic tumor [8] .
The incidence of DIC was 12.2% in 164 dogs with a malignant solid tumor, and that in human cases with a malignant solid tumor recently reported was 6.8% [10] and 10.9% [7] . Two reasons for the higher incidence of DIC in the dog cases were suspected. The first one is that activities of some coagulation factors, factor V, VII, VIII, IX, XI and XII in dogs might be much higher than those in humans, readily causing DIC in dogs [6] . The second is that DIC in our study was diagnosed depending only on laboratory findings of activation of the clotting and fibrinolytic systems, and DIC in human cases was detected both by laboratory and clinical findings including thrombosis and hemorrhage.
Twenty dogs with DIC included 7 dogs with hemangiosarcoma, 4 dogs with mammary gland carcinoma, 2 dogs each with adenocarcinoma of the lung and nasal adenocarcinoma, 1 dog each with squamous cell carcinoma, osteosarcoma, gastric carcinoma, granulose cell tumor and adrenal cortical carcinoma. The incidence of DIC in dogs with hemangiosarcoma, mammary gland carcinoma, adenocarcinoma of the lung, nasal adenocarcinoma, squamous cell carcinoma, osteosarcoma, gastric carcinoma, granulose cell tumor and adrenal cortical carcinoma was 46.7%, 28.5%, 50.0%, 11.1%, 6.3%, 12.5%, 33.3%, 50.0% and 50.0%, respectively. The incidence of DIC was significantly higher in (Table 2) . These results indicated that special care should be taken in looking for coagul a t i o n a b n o r m a l i t i e s a n d D I C i n d o g s w i t h hemangiosarcoma, mammary gland carcinoma, or adenocarcinoma of the lung. And care should also be taken care with dogs with other malignant tumors to look for coagulation abnormalities as well as DIC, since 56.3% of the dogs with a malignant tumor had abnormal coagulation findings in this study, including the dogs with DIC ( Table 1) and 83% of dogs with cancer were reported to have some abnormal coagulation [5] .
In 208 dogs with a malignant tumor, a low platelet count, prolonged PT, prolonged APTT, a low plasma fibrinogen concentration, low plasma AT III activity and high serum FDP was detected in 36, 33, 23, 43, 65 and 30 dogs, respectively (Table 3) . Furthermore, among DIC cases, a low platelet count was detected in 14 dogs (38.3%), prolonged PT in 15 dogs (45.5%), prolonged APTT in 16 dogs (69.6%), a low plasma fibrinogen concentration in 16 dogs (37.2%), low plasma AT III activity in 16 dogs (24.6%) and high serum FDP in 15 dogs (50.0%). Therefore, when APTT is prolonged, DIC would be most suspected in dogs with a malignant tumor. This study revealed that the incidence of DIC was 9.6% in dogs with a malignant tumor which was a solid tumor in all. In 164 dogs with a malignant solid tumor, the incidence of DIC was 12.2%. The incidence of DIC in dogs with hemangiosarcoma, mammary gland carcinoma and adenocarcinoma of the lung was significantly higher than that in dogs with other malignant tumors.
